CAH Q3 Beats, Guidance Raised, but Valuation Capped

What happened

Cardinal Health beat Q3 EPS estimates and raised its FY26 non-GAAP EPS view to at least $10, though revenue missed on lingering OptumRx effects. The specialty/MSO pivot continues to drive profit growth, with Pharma segment profit up 26% and "Other" segment surging 60%. However, the master report flags that this growth is increasingly acquisition-adjusted, with a widening GAAP/non-GAAP gap and rising leverage. The stock's ~22x FY26 EPS floor and 17.8x EV/EBITDA embed high expectations for flawless integration and benign policy outcomes, leaving little room for error. With the stock near the report's suggested trim zone above $210, the beat-and-raise may be a selling opportunity rather than a buy signal.

Implication

Over the next 6–18 months, the risk of multiple compression from policy headwinds, CVS concentration, or integration stumbles outweighs the potential for further upside; wait for pullbacks to the $185 attractive-entry zone.

Thesis delta

The Q3 beat and FY26 guidance raise confirm the near-term EPS trajectory, but the stock already prices in this growth at ~22x earnings. The master report's 'POTENTIAL SELL' rating is reinforced: the widening GAAP/non-GAAP gap, rising leverage, and crowded momentum sentiment suggest the risk/reward skews negative from here. Investors should use strength to pare positions rather than add, as any future guidance miss or policy shock could trigger sharp de-rating.